MX2021015292A - Interacciones terapeuticas de leucometiltioninio. - Google Patents
Interacciones terapeuticas de leucometiltioninio.Info
- Publication number
- MX2021015292A MX2021015292A MX2021015292A MX2021015292A MX2021015292A MX 2021015292 A MX2021015292 A MX 2021015292A MX 2021015292 A MX2021015292 A MX 2021015292A MX 2021015292 A MX2021015292 A MX 2021015292A MX 2021015292 A MX2021015292 A MX 2021015292A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- homeostatic
- downregulation
- therapeutics
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4848—Monitoring or testing the effects of treatment, e.g. of medication
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1909493.7A GB201909493D0 (en) | 2019-07-01 | 2019-07-01 | Therapeutic interactions |
| PCT/EP2020/068422 WO2021001380A1 (en) | 2019-07-01 | 2020-06-30 | Therapeutic interactions of leucomethylthioninium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021015292A true MX2021015292A (es) | 2022-01-18 |
Family
ID=67540109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021015292A MX2021015292A (es) | 2019-07-01 | 2020-06-30 | Interacciones terapeuticas de leucometiltioninio. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230031369A1 (https=) |
| EP (1) | EP3989954A1 (https=) |
| JP (1) | JP7638915B2 (https=) |
| KR (1) | KR20220027203A (https=) |
| CN (1) | CN114126622A (https=) |
| AU (1) | AU2020298758A1 (https=) |
| BR (1) | BR112021025256A2 (https=) |
| CA (1) | CA3143790A1 (https=) |
| GB (1) | GB201909493D0 (https=) |
| IL (1) | IL289338B1 (https=) |
| MX (1) | MX2021015292A (https=) |
| WO (1) | WO2021001380A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7073330B2 (ja) | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| FI4385512T3 (fi) | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100119D0 (en) | 2001-01-03 | 2001-02-14 | Univ Aberdeen | Materials and methods relating to protein aggregation in neurodegenerative disease |
| GB0106953D0 (en) | 2001-03-20 | 2001-05-09 | Univ Aberdeen | Neufofibrillary labels |
| ES2349322T7 (es) | 2006-03-29 | 2019-10-17 | Wista Lab Ltd | Sales de 3,7-diamino-10H-fenotiazina y su utilización |
| AU2008265045B2 (en) | 2007-06-19 | 2014-02-27 | Taurx Therapeutics Management Ltd. | Phenothiazine compounds for treating Mild Cognitive Impairment |
| CA2701075C (en) | 2007-10-03 | 2019-02-12 | Wista Laboratories Ltd. | Therapeutic use of diaminophenothiazines. |
| EP2227766A2 (en) | 2007-11-05 | 2010-09-15 | Wista Laboratories Ltd. | Systems for clinical trials |
| JP5898701B2 (ja) | 2011-02-11 | 2016-04-13 | ウィスタ ラボラトリーズ リミテッド | フェノチアジンジアミニウム塩およびそれらの使用 |
| JP7073330B2 (ja) * | 2016-07-25 | 2022-05-23 | ウィスタ ラボラトリーズ リミテッド | ジアミノフェノチアジンの投与及び投与量 |
| GB201614834D0 (en) * | 2016-09-01 | 2016-10-19 | Wista Lab Ltd | Treatment of dementia |
| FI4385512T3 (fi) * | 2018-07-26 | 2026-01-12 | Taurx Therapeutics Man Ltd | Diaminofenotiatsiinien optimoitu annostus populaatioille |
-
2019
- 2019-07-01 GB GBGB1909493.7A patent/GB201909493D0/en not_active Ceased
-
2020
- 2020-06-30 MX MX2021015292A patent/MX2021015292A/es unknown
- 2020-06-30 CN CN202080048557.6A patent/CN114126622A/zh active Pending
- 2020-06-30 JP JP2021577641A patent/JP7638915B2/ja active Active
- 2020-06-30 KR KR1020227003213A patent/KR20220027203A/ko not_active Ceased
- 2020-06-30 WO PCT/EP2020/068422 patent/WO2021001380A1/en not_active Ceased
- 2020-06-30 US US17/620,949 patent/US20230031369A1/en not_active Abandoned
- 2020-06-30 EP EP20739286.1A patent/EP3989954A1/en active Pending
- 2020-06-30 CA CA3143790A patent/CA3143790A1/en active Pending
- 2020-06-30 BR BR112021025256A patent/BR112021025256A2/pt unknown
- 2020-06-30 AU AU2020298758A patent/AU2020298758A1/en active Pending
-
2021
- 2021-12-23 IL IL289338A patent/IL289338B1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3989954A1 (en) | 2022-05-04 |
| KR20220027203A (ko) | 2022-03-07 |
| JP7638915B2 (ja) | 2025-03-04 |
| IL289338A (en) | 2022-02-01 |
| IL289338B1 (en) | 2026-03-01 |
| CN114126622A (zh) | 2022-03-01 |
| WO2021001380A1 (en) | 2021-01-07 |
| JP2022538642A (ja) | 2022-09-05 |
| GB201909493D0 (en) | 2019-08-14 |
| AU2020298758A1 (en) | 2022-02-24 |
| BR112021025256A2 (pt) | 2022-01-25 |
| US20230031369A1 (en) | 2023-02-02 |
| CA3143790A1 (en) | 2021-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2021252538A3 (en) | Advantageous benzofuran compositions for mental disorders or enhancement | |
| MX2024010140A (es) | Nuevos metodos. | |
| ZA202204929B (en) | Rimegepant for cgrp related disorders | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| MX2023007998A (es) | Regimenes de tratamiento con dexmedetomidina. | |
| EA201650134A1 (ru) | Специфическая сочетанная терапия злокачественных опухолей цитостатиком и его модификатором | |
| MA44612B1 (fr) | Méthodes de traitement de cancers pédiatriques | |
| RU2014150942A (ru) | Лечение побочных эффектов в виде моторных и двигательных расстройств, связанных с лечением болезни паркинсона | |
| ZA202304965B (en) | Combination therapy for treating cancer | |
| JOP20230276A1 (ar) | تركيبات وطرق لعلاج الاكتئاب | |
| MX2020006309A (es) | Fórmulaciones de parasiticida de isoxazolina y métodos para el tratamiento de la blefaritis. | |
| MX2023010711A (es) | Fenalquilaminas y métodos de preparación y uso de las mismas. | |
| MX2010009624A (es) | Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1 y cx3cr1. | |
| MX2023003993A (es) | Tratamiento de trastornos bipolares y psicosis con clorhidrato de dexmedetomidina. | |
| JOP20220259A1 (ar) | تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها | |
| MX2021008081A (es) | Tratamiento de la enfermedad de sjogren con proteinas de fusion de nucleasa. | |
| BR112021025701A2 (pt) | Formulações e métodos de parasiticida de isoxazolina para tratar blefarite | |
| MX2021015292A (es) | Interacciones terapeuticas de leucometiltioninio. | |
| MX2024000701A (es) | Metodos de tratamiento de la enfermedad de alzheimer. | |
| MX2025002727A (es) | Escilo-inositol en combinación con inmunoterapéuticos para el tratamiento de la enfermedad de alzheimer | |
| MX2022012001A (es) | Tratamiento preventivo de la migra?a. | |
| JOP20240081A1 (ar) | مُعدِّلات الجزيئات الصغيرة لنشاط الجلوكوسيريبروسيد واستخداماتها | |
| MX2023002350A (es) | Composiciones y metodos para mejorar enfermedades y trastornos neurologicos. | |
| MX2021011289A (es) | Composiciones que comprenden moduladores de isoenzima m2 muscular de piruvato cinasa pkm2 y metodos de tratamiento que usan las mismas. | |
| PH12020550722A1 (en) | Ophthalmic topical composition comprising dobesilic acid for treating diseases of the posterior segment of the eye |